Synopsis:-Posting its strongest annual performance on record, a precision plastics manufacturer reported FY26 consolidated revenue of Rs.990.7 crore and net profit of Rs.169.9 crore, up 83 percent year-on-year, driven by a sharp surge in healthcare and drug-delivery products, even as weakness in European and US home furnishings markets weighed on its consumer business.
A precision plastics manufacturer drew investor attention after reporting strong FY26 and Q4 results, driven by rapid expansion in its healthcare and drug-delivery business. The company also marked its entry into the semiconductor supply chain and continued diversifying into high-precision manufacturing segments, strengthening its positioning beyond traditional consumer-focused applications.
With a market capitalization of Rs. 12,600 crore, the shares of Shaily Engineering Plastics were trading at Rs. 2,828.25 per share, jumping by 18 percent from its day low of Rs. 2,396.23 apiece. It is trading at a P/E of approx. 78x. Ace investor Ashish Kacholia holds a 5.2% stake in Shaily Engineering Plastics. It is the highest holding value in his portfolio.
Q4 and FY26 Financial Performance
Shaily Engineering Plastics delivered a strong FY26 performance, with consolidated revenue rising 26 percent YoY to Rs. 990.7 crore from Rs. 786.8 crore in FY25, driven largely by rapid growth in its healthcare business. EBITDA surged 61 percent to Rs. 287.7 crore, while EBITDA margins expanded sharply to 29 percent from 22.7 percent due to a better product mix and improved operating leverage. Profit after tax jumped 83 percent YoY to Rs. 169.9 crore, with the healthcare segment emerging as the key growth driver as revenue from the segment surged 139 percent during the year.
The company has also announced a dividend of Rs. 3 on a face value of Rs. 2 (150%), subject to approval of shareholders in the forthcoming Annual General Meeting.
The company maintained strong momentum in Q4 FY26, reporting consolidated revenue growth of 9 percent YoY to Rs. 236.8 crore. EBITDA increased 27 percent to Rs. 69.3 crore, while PAT rose 40 percent YoY to Rs. 40.2 crore, supported by continued margin expansion and strong healthcare traction. During the quarter, the company secured a Rs. 423 crore pen injector order from a domestic pharma company, launched Semaglutide-related products across multiple markets, and expanded into semiconductor manufacturing through a supply agreement with a Korean company.
The Healthcare Engine
Healthcare remained the company’s key growth driver, led by strong traction in GLP-1 therapies and drug-delivery products. During the year, the company launched Harmony and Neo pen injectors for Semaglutide across multiple markets, while a customer in Canada also launched Semaglutide pens supplied by the company.
The company further strengthened its pharma positioning after receiving a Rs. 423 crore pen injector order from a domestic pharmaceutical company over four years. It also expanded into precision-led segments such as semiconductor trays and consumer electronics components, supporting future diversification.
New Bets Beyond Healthcare
Shaily Engineering Plastics is actively expanding beyond healthcare into high-precision manufacturing segments to diversify its revenue base. During Q4 FY26, the company signed an agreement with a Korean firm for the manufacture and supply of semiconductor trays, marking its entry into the global semiconductor supply chain. It also commenced commercial supplies to a consumer electronics customer, strengthening its presence in electronics-focused manufacturing applications.
To support future expansion, the board approved an enabling resolution to raise up to Rs. 500 crore through equity shares or convertible instruments via routes such as QIP or preferential allotment. Management stated that the proposed fundraiser would provide flexibility to capitalize on growth opportunities across healthcare, semiconductor, consumer electronics, and other emerging precision-engineering verticals.
Technical Overview
The stock’s Immediate support is placed near Rs.2,342.20, while Rs.2,796.20 remains the Closest resistance level. Price movement near these levels may determine the stock’s near-term trading range and overall market direction.
Conclusion
With healthcare rapidly emerging as its primary growth engine and new opportunities opening up in semiconductor and precision manufacturing, Shaily Engineering Plastics is steadily evolving into a diversified high-value engineering platform. Backed by expanding global pharmaceutical relationships, growing presence in regulated markets, and continued investments in future-focused segments, the company appears well positioned to strengthen its long-term growth trajectory.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Stock Jumps 18% From Day’s Low After Net Profit Surges 83% YoY; Forays into Semiconductor Segment appeared first on Trade Brains.